Lexicon Pharmaceuticals (LXRX) Jefferies Global Healthcare Conference 2025 summary

Strategic partnerships and financial updates

• Secured an exclusive worldwide license for LX9851, a novel obesity asset, with Novo Nordisk, providing significant financial flexibility and validation of the science.

• Partnership with Viatris is progressing well, with filings for sotagliflozin in UAE, Saudi Arabia, and plans for Canada and Australia, supporting global expansion.

• Ended Q1 with just under $195 million in cash, with funding in place for milestone-generating tasks this year.

• Expecting $30 million in near-term milestones from the Novo Nordisk deal, following a $45 million upfront payment.

• Phase III program for pilavapadin is expected to be conducted with a partner, not currently included in forward budgeting.

Pipeline progress and clinical milestones

• Pilavapadin showed significant pain reduction in DPNP, with a 1.5–2 point drop in pain scores and high completion rates at the 10 mg dose.

• Secondary analyses and full data from the PROGRESS phase II-B study will be presented at major medical meetings in the second half of the year.

• FDA meeting for pilavapadin phase III planning expected around late Q3 to early Q4, with a two-arm trial design to minimize placebo effect.

• Sotagliflozin's SONATA phase III study in hypertrophic cardiomyopathy (HCM) is enrolling both obstructive and non-obstructive patients, with data readout expected in 2027.

• Sota's broad applicability in HCM and heart failure, with potential for first approval in non-obstructive HCM, positions it for wide adoption.

Market positioning and commercialization plans

• Sota's known safety profile and ease of use could enable broad prescribing by cardiologists, unlike niche therapies.

• Potential for up to 20% higher pricing in HCM compared to heart failure, with focus on gross-to-net management.

• Differentiation from other SGLT2 inhibitors through dual inhibition and unique mechanistic data, supported by MACE outcomes and broad indications.

• Commercialization options for sotagliflozin remain open, with internal expertise and potential for partnerships.

• Ongoing focus on resource discipline and proactive deal-making to maximize pipeline value.